Posted by Michael Wonder on 27 Mar 2019
NICE recommendation for Steglatro in type 2 diabetes mellitus
27 March 2019 - NICE has recommended MSD’s Steglatro (ertugliflozin) for use within the NHS, for the treatment of adults with type 2 diabetes mellitus.
The recommendation for the sodium-glucose cotransporter-2 (SGLT-2) inhibitor is as monotherapy in adults with type II diabetes that cannot tolerate metformin, or as part of a dual therapy regimen in combination with metformin.
The treatment offers a new option for people with the disorder with a 20% lower acquisition cost than other SGLT-2 inhibitors, with the price of a once daily dose costing just £29.40 for 28 days' treatment.
